Background. The 10-valent pneumococcal conjugate vaccine (PHiD-CV10) was introduced in Iceland in 2011, without catch-up. The aim of this study was to estimate vaccine impact (VI) on acute otitis media (AOM).
The aim of this whole-population study was to evaluate the vaccine impact of PHiD-CV10 on all-cause AOM in children <3 years of age in Iceland.
MATERIALS AND METHODS

Data Sources
This is a whole-population, individual-level, observational cohort study of primary care visits due to AOM in children <3 years of age. The study encompasses the period between 1 January 2005 and 31 December 2015. All children born in Iceland in 2005 through 2015 were included and followed until 3 years of age, or until the end of the study period. A visit was defined to be due to AOM if an International Classification of Diseases, Tenth Revision (ICD-10) diagnostic code of suppurative otitis media (H66) was recorded by a physician. Repeated visits within 30 days from the initial visit were considered to be the same episode and excluded from the analysis.
Information on visits was extracted from the primary healthcare database of the Icelandic Directorate of Health, which includes all 69 primary care health clinics in Iceland. Private pediatric clinics were not included due to coding differences. Data included all ICD-10 codes linked to the visit as well as demographic information. Children were identified using their unique government-issued national identification numbers, which enabled tracking both chronologically and by primary care location. Temporary residents and travelers without national identification numbers were excluded to remove possible bias due to the increase in tourism in Iceland over the study period. Population demographic information was obtained from Statistics Iceland (www.statice.is).
Statistical Methods
Analyses were performed either on individual birth cohorts or on grouped cohorts based on vaccine eligibility. Birth cohorts 2005-2010 were grouped as vaccine noneligible (VNEC) and birth cohorts 2011-2015 as vaccine eligible (VEC). Statistical analysis was performed in R version 3.3.2 software using the survival package [28] .
Crude Incidence Rate and Cumulative Incidence
Crude incidence rates (IRs) were calculated per 100 PY at risk for each birth cohort, stratified by 4-month age brackets. Crude incidence rate ratios (IRRs) between VNEC and VEC were also calculated, and confidence intervals (CIs) estimated assuming the Poisson distribution. The cumulative incidence of children experiencing 0-12 episodes of AOM before 3 years of age was calculated and compared using the χ 2 test of homogeneity. Because birth cohorts 2013-2015 did not have complete follow-up time at the time of writing, they were excluded from the analysis of cumulative incidence. Additionally, the crude incidence risk ratio of experiencing 0, 1-4, or >5 episodes of AOM before 3 years of age was calculated, and CIs adjusted for multiple testing using the Bonferroni correction.
Regression Analysis
The Andersen-Gill extension of the Cox regression model for repeated events [29] was used to model the data on the individual level and to account for censoring of follow-up time. Sandwich variance estimates were used to correct for correlation between successive visits by the same individual. The model was used to estimate the hazard ratio (HR) of AOM visits of each birth cohort compared to the last vaccine-noneligible cohort (2010 cohort, reference cohort), correcting for both gender and the number of previous AOM episodes. The overall vaccine impact of PHiD-CV10 on AOM was calculated using 1 -(HR between the last included vaccine-eligible birth cohort [2015 cohort] and the reference cohort) × 100%.
To characterize the mechanism by which the vaccine reduces the risk of AOM, the HR between VNEC and VEC was calculated, stratified by the number of previous AOM episodes.
Finally, the mean number of AOM episodes by age for both VNEC and VEC was calculated from the model using the generalized Nelson-Aalen estimator [29] . The absolute number of AOM episodes prevented by the vaccination in the first 5 years of the intervention was determined by multiplying each child's follow-up time by the corresponding mean number of episodes. The absolute IR reduction was then calculated by dividing the number of prevented episodes with the total person-time of the VEC.
The study was approved by the National Bioethics Committee (VSNb2013010015/03.07),95 and the National Data Protection Authority (2013010100VEL/-).
RESULTS
The study included 53 150 children who contributed 140 912 PY of follow-up time. A total of 74 802 visits for AOM were recorded, of which 16 008 were repeated visits within 30 days. After the exclusion of repeated visits, 58 794 episodes of AOM remained.
Crude Incidence Rate and Cumulative Incidence
The overall crude IR of AOM for the whole study period was 41.7 per 100 PY; 43.6 in the VNEC and 38.0 in the VEC. The IRs for the first, second, and third year of life for the VNEC and VEC are shown in Table 1 . The IR was lowest in children <4 months of age, and highest in children 8-11 and 12-15 months of age. It decreased significantly in all age brackets following vaccination ( Figure 1 ). The largest decrease was noted in children <4 months of age (40% [95% CI, 31%-49%]), from 5.60 to 3.33 cases per 100 PY. In other age brackets, the decrease was 6%-23% ( Figure 1 ).
The cumulative incidence of AOM episodes between VNEC and VEC differed significantly (χ 2 test 56.1, P < .001).
The proportion of children who experienced >5 episodes of AOM decreased, with a corresponding increase in children who did not experience a single episode of AOM. The incidence proportion and crude incidence risk ratio of experiencing 0, 1-4, and >5 episodes of AOM are shown in Table 2 .
Regression Analysis
Model diagnostic testing did not reveal significant deviations from the model assumptions By 3 years of age, the mean number of AOM episodes per child in the VNEC and VEC was 1.61 and 1.37, respectively. The mean number of episodes from birth to 3 years of age is displayed in Figure 3 . The difference in the mean number of episodes between VNEC and VEC was significant from birth, and increased as the child aged. The absolute number of prevented episodes of AOM in children <3 years of age in the first 5 years of the intervention was 4187 (95% CI, 3363-5011), and the absolute IR reduction was 8.4 episodes per 100 PY (95% CI, 6.78-10.1).
DISCUSSION
In this whole-population study, we have demonstrated a 22% vaccine impact of PHiD-CV10 on all-cause AOM. The vaccine is associated with a significant reduction in the first and second episodes of AOM, but does not prevent further episodes in those who have already experienced ≥2 episodes. There were significant reductions in the crude IR of AOM in all age brackets, including a 40% (95% CI, 31%-49%) reduction in children too young to receive direct vaccine protection. This suggests that herd protection was induced by the vaccination. The present study is strengthened by several factors. It follows 11 consecutive birth cohorts until 3 years of age through a whole-country population registry of primary care visits, using a broad definition of AOM. Generally, RCTs evaluating the efficacy of PCV against AOM report larger effect sizes the more restrictive their outcome measure. RCTs have reported larger vaccine efficacy (57%-70%) [15, [17] [18] [19] against vaccine-type pneumococcal AOM than against pneumococcal AOM (34%-56%) [16, 18] . The efficacy estimates against allcause AOM are less still, from 8% to 34% [17, 18, 20] . When evaluating the outcome measure of all-cause AOM, many RCTs use more stringent diagnostic criteria than is generally adhered to in the community setting, often employing certified otoscopists to diagnose what general physicians normally do. Though more accurate, these studies are inadequate when informing public policy or determining cost-effectiveness. Observational studies have shown a larger impact of PCV on all-cause OM, with vaccine impact estimates of from 14% to 57% [22, 24, 25] . However, these studies may be biased due to case ascertainment and unclear study populations. Our study addresses the least restrictive definition of AOM-all-cause, physician-diagnosed AOM-and its study population contains all children <3 years of age in Iceland, with no known exceptions.
Another strength of this study is the individual based nature of the data, which allows for data collection on a single child through multiple visits regardless of location or time. This permits the use of sophisticated survival analysis methods normally reserved for experimental studies. Using these methods, the correlation between successive AOM episodes can be taken into account, an analysis which is unfeasible in conventional observational studies.
We show that PHiD-CV10 reduces the incidence of AOM through its impact on the first and second episodes of AOM. No independent effect was noted on subsequent AOM episodes in those who had already experienced ≥2 episodes. Streptococcus pneumoniae is adept in causing AOM in previously healthy middle ears and is often the cause of a child's first episode [13, 14] . This initial AOM episode is believed to cause injury to the middle ear, making it susceptible to AOM by other, less virulent pathogens. The observed independent protection of PHiD-CV10 against the first and second AOM episode, and not subsequent episodes, may therefore be explained by the middle ear injury incurred by initial pneumococcal AOM. This in turn induces susceptibility to other pathogens, against which PHiD-CV10 offers no protection. The proportion of children in the VEC who have never experienced an episode of AOM by 3 years of age is significantly higher than those in the VNEC (IRR: 1.08 [98.3% CI, 1.05-1.12]). We also show the mean number of AOM episodes as a function of age for both the vaccine-noneligible and vaccine-eligible cohorts, and use this to estimate the absolute number of averted episodes of AOM. On average, each episode of AOM resulted in 1.26 physician visits within 30 days. As repeated visits within 30 days were excluded from the analysis, the actual number of averted physician visits is considerably higher than reported here.
The reported crude incidence of AOM varies up to 10-fold between studies in different countries and settings [24] . There are several possible cultural and economic reasons for this variance. Factors such as access to and cost of healthcare can mean portions of populations delay or eschew physician visits for mild disease [30, 31] . This is not the case in Iceland, where healthcare is guaranteed for all permanent residents, access to urgent care is excellent, and primary care for children is free of charge. These advantages, combined with the fact that generally both parents are fully employed and enrollment of Icelandic children in daycare is high, may increase the likelihood of early medical intervention for mild disease. The Organisation for Economic Co-operation and Development (OECD) ranks Iceland second in formal daycare attendance with up to 60% of children <3 years of age attending for 38 hours per week, compared to the OECD average of 35% attendance for 30 hours [32] . Both attendance and hours per week are known risk factors for AOM [33, 34] . Finally, the pneumococcal carriage rate is also higher in Iceland than in most developed countries [35] . Reflecting these cultural and economic differences, the crude postvaccination incidence rate reported in this study, 30.0 per 100 PY, is lower than previously reported incidence from Iceland (63-70 per 100 PY) [6] and the United States and Canada (42-122 per 100 PY) [4, 5, 8] , but higher than in other European countries and in New Zealand (16-33 per 100 PY) [2, 3, 36, 37] .
In addition to the reduction in IR noted in all age brackets of vaccinated children, we also observed a significant 40% reduction in the IR of AOM in children <4 months of age following vaccine introduction. This provides evidence for a herd effect, as children in this age group are too young to have direct protection from the vaccination [38] . There is a paucity of published data regarding herd effect of PCV against AOM [19, 39] . A recent study reported fewer positive pneumococcal cultures from middle ear fluid samples in children <4 months of age after the introduction of PCV, suggesting a possible herd effect [21] . The results of our study strengthen that earlier suggestion.
Several factors must be considered when interpreting the study results. First, the impact of vaccination status was not modeled directly; rather, the vaccine eligibility of birth cohorts was used as a proxy for vaccination status. We argue that there is strong evidence for the validity of this proxy measure, as <1% of children in the early VNECs were vaccinated compared with >97% of children in the VECs [27] . The proportion of vaccinated children was slightly higher in the last 2 VNECs, with 9% of children in the 2009 cohort and 19% in the 2010 cohort vaccinated. This increase may be due to heightened interest in pneumococcal vaccination as its inclusion into the pediatric vaccination program in Iceland in 2011 was imminent. In any case, this would likely bias the vaccine impact estimate downward, if at all, as the 2010 cohort was used as the reference.
Second, due to the observational nature of the study, it is not possible to exclude the possibility that coding practices or healthcare-seeking behavior might have changed during the study period. Reductions in AOM diagnoses have been reported worldwide since the millennium [24] . This gives reason to suspect that some of study's observed effect may be due to secular trends. However, this does not seem to be supported by the data. The study's results are summarized in Figures 1  and 2 , showing, respectively, the crude incidence and hazard of AOM episodes by birth cohort. When each birth cohort is compared to the last VNEC (2010) using the individual data corrected for gender and censored observations, it becomes clear that there exists little variation in the hazard of AOM between individual noneligible birth cohorts. Only the 2007 birth cohort is significantly different from the 2010 cohort, and there is even less difference between proximal cohorts. In contrast, there is an abrupt drop in the hazard of AOM in the first vaccine-eligible birth cohort (2011) compared to 2010, and the hazard of each VEC is significantly decreased. In 2009, updated guidelines on AOM were published by the Icelandic Directorate of Health [40] . After these guidelines were issued, it is possible that AOM diagnoses became more restricted. This hypothesis, however, is not supported by our data. The hazard of AOM in the 2009 and 2010 birth cohorts is not significantly different than the other VNECs. Furthermore, as the 2010 cohort was used as a reference in calculating the vaccine impact estimate, the guidelines cannot be considered a confounder. An increase in private physician visits could present another potential bias, as private visits could not be included in the study due to differences in diagnostic coding. However, this is unlikely to be significant. Although information from Statistics Iceland (http://statice.is/statistics/society/health/healthcare) shows an increasing number of total visits to private pediatricians in recent years, the number of after-hours and emergency visits has remained stable at around 11 000 visits each year for children <18 years of age (personal correspondence with head of the only after-hours/emergency pediatric clinic). This indicates that the increase is due to planned nonemergency visits rather than emergency ones, such as AOM.
CONCLUSIONS
This study, which follows 11 consecutive Icelandic birth cohorts (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) up to 3 years of age, demonstrates a 22% vaccine impact of PHiD-CV10 on all-cause AOM, and provides evidence of herd effect against AOM in children too young to receive direct protection. The impact is shown to be mediated through an independent effect on the first and second episodes of AOM, but no significant effect is noted for subsequent episodes. 
